NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

Core Viewpoint - DJS Law Group is investigating Dyne Therapeutics for potential violations of securities laws following a significant drop in share price after the company announced revised trial protocols [1][2]. Investigation Details - The investigation centers on whether Dyne Therapeutics made misleading statements or failed to disclose critical information to investors [2]. - Following a June 17, 2025 announcement regarding feedback from the FDA and new efficacy data, Dyne's shares fell by over 19.4% during intraday trading on the same day [2]. Company Background - DJS Law Group specializes in enhancing investor returns through legal advocacy, focusing on securities class actions, corporate governance litigation, and M&A appraisals [4].

Company Overview - Hims & Hers Health, Inc. is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [3]. Recent Developments - On June 23, 2025, Novo Nordisk A/S announced the termination of its collaboration with Hims & Hers due to concerns regarding illegal mass compounding and deceptive marketing practices [3]. - Following this announcement, Hims & Hers' stock price experienced a significant decline of over 34% [3]. Legal Investigation - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1].

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Compass Diversified Holdings (NYSE: CODI) publicly traded securities between May 1, 2024 and May 7, 2025, both dates inclusive (the “Class Period”), have until Tuesday, July 8, 2025 to seek appointment as lead plaintiff of the Compass Diversified class action lawsuit. Captioned Augenbaum v. Compass Diversified Holdings, No. 25-cv-01003 (C.D. Cal.), the Compass Diversified c ...

Core Viewpoint - The article discusses a class action lawsuit against Vestis Corporation due to significant stock price decline following disappointing financial results and misleading statements made by the company regarding its growth and revenue guidance [2][3]. Group 1: Financial Performance - On May 7, 2025, Vestis reported its second quarter fiscal 2025 financial results, revising its growth and revenue guidance for 2025, which fell significantly below market expectations [2]. - The company attributed the poor results to "lost business in excess of new business" and "lower adds over stops," indicating a decline in revenue from existing customers [2]. Group 2: Stock Price Impact - Following the announcement of the disappointing financial results, Vestis's stock price dropped by $3.27, or 37.5%, closing at $5.44 per share on May 7, 2025, resulting in losses for investors [2]. Group 3: Lawsuit Details - The class action lawsuit alleges that during the Class Period, Vestis made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specifically, the lawsuit claims that the company was not equipped to achieve its growth guidance, leading to a significant revenue decline from existing customers, which rendered the positive statements misleading [3]. Group 4: Legal Action - Investors who purchased Vestis securities during the Class Period have until August 8, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following the FDA announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages for class members over its 85-year history [4]

Group 1 - Dyne Therapeutics is under investigation by Pomerantz LLP for potential securities fraud or unlawful business practices involving its officers and directors [1] - On June 17, 2025, Dyne announced a delay in filing for FDA approval of its experimental therapy DYNE-101 for myotonic dystrophy type 1, revising its enrollment timeline for the Phase 1/2 global ACHIEVE trial [3] - Following the announcement of the delay, Dyne's stock price dropped by $2.96, or 21.42%, closing at $10.86 per share [4] Group 2 - The revised schedule for the ACHIEVE trial indicates that Dyne now aims to complete enrollment in the fourth quarter of 2025, with data readout expected in mid-2026 and a potential Accelerated Approval submission in late 2026 [3]

Core Viewpoint - UroGen Pharma Ltd. is under investigation for potential securities fraud and unlawful business practices following negative FDA feedback on its bladder cancer drug UGN-102 [1][3]. Group 1: FDA Review and Trial Concerns - The FDA's briefing document highlighted that UroGen's Envision trial lacked a concurrent control arm, making the primary endpoints difficult to interpret [3]. - The FDA recommended a randomized trial design multiple times to address concerns regarding the trial's validity [3]. Group 2: Stock Price Impact - Following the FDA's briefing document release on May 16, 2025, UroGen's stock price dropped by $2.54, or 25.79%, closing at $7.31 per share [4]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102 on May 21, 2025, the stock price fell further by $3.37, or 44.7%, closing at $4.17 per share [4].

BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors who have lost money in their Hims & Hers Health, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/hims. What is this all about? Shares of Hims & Hers Health fell over 25% on June 23 after Novo Nordisk announced it was terminating its partnership ...